Evidence map›Paper›PMID 41423547›Full record

ArticleDiabetologia2026

Islet amyloid disrupts MHC class II antigen presentation and delays autoimmune diabetes in NOD mice.

Heather C Denroche, Victoria Ng, Jane Velghe, Imelda Suen, Liam Stanley, Dominika Nackiewicz, Mitsuhiro Komba, Derek L Dai, Galina Soukhatcheva, Sam Chen and 1 more

Abstract read
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Heather C DenrocheCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-0976-2656
Victoria NgCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Jane VelgheCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Imelda SuenCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Liam StanleyCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Dominika NackiewiczCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Mitsuhiro KombaCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Derek L DaiCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Galina SoukhatchevaCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Sam ChenIntegrated Nanotherapeutics Inc., Burnaby, BC, Canada.
C Bruce VerchereCanucks for Kids Fund Childhood Diabetes Laboratories, BC Children's Hospital Research Institute, Department of Surgery, University of British Columbia, Vancouver, BC, Canada. bverchere@bcchr.ca.ORCID http://orcid.org/0000-0002-9262-0586

Funding

CIHR PJT-165943Juvenile Diabetes Research Foundation International 3-APF-2018-586-A-NJuvenile Diabetes Research Foundation International 3-PDF-2014-191-A-N
6 · The paper itself

Abstract

aims/hypothesisIslet amyloid contributes to beta cell failure in type 2 diabetes through several mechanisms, one being the potent induction of local islet inflammation through activating inflammatory pathways in islet macrophages. As islet amyloid has recently been reported in pancreases of people with type 1 diabetes, and islet macrophages are thought to play a role in the pathogenesis of type 1 diabetes, we sought to understand the impact of islet amyloid on islet macrophages and beta cell autoimmunity.

methodsWe performed an unbiased phenotypic investigation of islet macrophages in the early stage of islet amyloid formation using single-cell RNA-seq of resident islet macrophages in mice with and without the amyloidogenic form of human islet amyloid polypeptide (hIAPP). The role of islet amyloid in autoimmune diabetes and antigen presentation was assessed in hIAPP-expressing NOD mice and in antigen-presenting cells ex vivo.

resultsMHC class II (MHCII) antigen presentation genes were strongly downregulated in islet macrophages during islet amyloid formation. NOD mice expressing an hIAPP transgene had delayed diabetes relative to littermate controls (median onset 30.3 vs 19.5 weeks, p=0.016). Likewise, physiological expression of hIAPP by genetic knockin also delayed diabetes in NOD mice relative to littermate controls (median onset 28.2 vs 18.0 weeks, p=0.049), corresponding with decreased markers of antigen presentation and activation, as well as decreased immune cell infiltration in islets. Adoptive transfer studies showed that systemic autoimmune function remained intact and beta cells from hIAPP transgenic mice did not evade immune recognition by diabetogenic T cells, collectively indicating the protection from diabetes was mediated by decreased antigen presentation in the pancreas. Consistent with this, incubation of dendritic cells with islet amyloid polypeptide (IAPP) aggregates decreased MHCII surface expression and diminished antigen-specific T cell activation through a phagocytosis-dependent mechanism. CONCLUSIONS/

interpretationCollectively, our data reveal a novel role for IAPP aggregates in decreasing MHCII antigen presentation and show that despite the well-established proinflammatory response of macrophages to IAPP aggregates, the uptake of IAPP aggregates during early amyloid formation also disrupts beta cell autoimmunity and delays diabetes in NOD mice.

Indexed as

Antigen PresentationDiabetes Mellitus, Type 1Histocompatibility Antigens Class IIIslet Amyloid PolypeptideIslets of LangerhansAnimalsAutoimmunityFemaleHumansInsulin-Secreting CellsMacrophagesMiceMice, Inbred NODMice, TransgenicHistocompatibility Antigens Class IIIslet Amyloid PolypeptideAntigen presentationIslet amyloidIslet macrophageMHC class IINODType 1 diabetes

Identifiers

PMID41423547
PMCPMC12957008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.